Repligen (NASDAQ:RGEN) Updates FY24 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.50-1.58 for the period, compared to the consensus estimate of $1.44. The company issued revenue guidance of $630-639 million, compared to the consensus revenue estimate of $629.61 million.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of research reports. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. UBS Group dropped their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Finally, Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Down 0.8 %

Shares of Repligen stock opened at $139.51 on Tuesday. Repligen has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The stock has a market cap of $7.81 billion, a price-to-earnings ratio of -3,487.75, a PEG ratio of 4.04 and a beta of 0.96. The firm’s 50-day moving average is $141.56 and its two-hundred day moving average is $145.05.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.